Literature DB >> 11815589

In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.

Tanja Schülin1.   

Abstract

Three hundred and eighty-five mucoid and non-mucoid strains of Pseudomonas aeruginosa isolated from 192 sputa from 57 adult cystic fibrosis patients were studied. Susceptibility testing using an agar dilution technique was performed for ceftazidime, ciprofloxacin, fosfomycin, meropenem and piperacillin, and the aerosolized agents colistin and tobramycin. Meropenem, ceftazidime and piperacillin were the most potent agents (susceptibility 86.2%, 84.2% and 84%, respectively). Tobramycin and colistin susceptibility rates were lower, but in light of higher intrabronchial concentrations of these drugs a greater percentage of strains might still be clinically susceptible. Only 46.2% and 41.8% of isolates were susceptible to ciprofloxacin and fosfomycin, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815589     DOI: 10.1093/jac/49.2.403

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

Review 1.  Aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 2.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

3.  Genetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium.

Authors:  Song Sun; Aurel Negrea; Mikael Rhen; Dan I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

4.  Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

Authors:  Dominic Hill; Barbara Rose; Aniko Pajkos; Michael Robinson; Peter Bye; Scott Bell; Mark Elkins; Barbara Thompson; Colin Macleod; Shawn D Aaron; Colin Harbour
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 5.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

6.  Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Authors:  Samuel M Moskowitz; Elizabeth Garber; Yunhua Chen; Sarah A Clock; Setareh Tabibi; Amanda K Miller; Michael Doctor; Lisa Saiman
Journal:  J Antimicrob Chemother       Date:  2010-04-29       Impact factor: 5.790

Review 7.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

8.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; S B Duffull; M Kinzig-Schippers; U Holzgrabe; U Stephan; G L Drusano; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

10.  Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.

Authors:  David L MacLeod; Lynn M Barker; Jennifer L Sutherland; Suzanne C Moss; Jesse L Gurgel; Thomas F Kenney; Jane L Burns; William R Baker
Journal:  J Antimicrob Chemother       Date:  2009-08-13       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.